197 related articles for article (PubMed ID: 21829581)
1. The short-term impact of Ontario's generic pricing reforms.
Law MR; Ystma A; Morgan SG
PLoS One; 2011; 6(7):e23030. PubMed ID: 21829581
[TBL] [Abstract][Full Text] [Related]
2. Money left on the table: generic drug prices in Canada.
Law MR
Healthc Policy; 2013 Feb; 8(3):17-25. PubMed ID: 23968624
[TBL] [Abstract][Full Text] [Related]
3. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
4. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
Zhang W; Sun H; Guh D; Anis AH
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
[TBL] [Abstract][Full Text] [Related]
5. New generic pricing scheme maintains high prices and risks of shortages.
Morgan SG; Persaud N
CMAJ; 2018 Apr; 190(14):E410-E411. PubMed ID: 29632033
[No Abstract] [Full Text] [Related]
6. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
7. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
8. Ontario's plunging price-caps on generics: deeper dives may drown some drugs.
Anis A; Harvard S; Marra C
Open Med; 2011; 5(3):e149-52. PubMed ID: 22046229
[TBL] [Abstract][Full Text] [Related]
9. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
10. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
11. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
Chen CL; Chen L; Yang WC
BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
[TBL] [Abstract][Full Text] [Related]
12. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
13. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
15. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
16. Generic Price Regulation and Drug Expenditures: Evidence From Canada.
Li Y
Value Health; 2023 Jun; 26(6):833-840. PubMed ID: 36706953
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
[TBL] [Abstract][Full Text] [Related]
18. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
Morgan SG; Li W; Yau B; Persaud N
CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
[TBL] [Abstract][Full Text] [Related]
19. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Bendicksen L; Rome BN; Avorn J; Kesselheim AS
Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
Wu J; Xu J; Liu G; Wu J
Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]